Cargando…

Case report: Indolent drug-related pneumonitis with alectinib therapy in the treatment of non-small cell lung cancer

Molecular targeting therapy is becoming the standard of care for some patients with anaplastic lymphoma kinase (ALK)-rearranged lung adenocarcinoma. Drug-related pneumonitis (DRP) has been identified as an infrequent but potentially severe adverse effect. Herein, we report a 50-year-old woman with A...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Xianmeng, Xia, Daqing, Jiang, Xuqin, Cao, Lejie, Ryu, Jay H., Hu, Xiaowen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9663455/ https://www.ncbi.nlm.nih.gov/pubmed/36386178 http://dx.doi.org/10.3389/fphar.2022.944685

Ejemplares similares

Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer
por: Hu, Yan, et al.
Publicado: (2022)

Safety of lorlatinib following alectinib-induced pneumonitis in two patients with ALK-rearranged non-small cell lung cancer: a case series
por: Myall, Nathaniel J., et al.
Publicado: (2021)

Case Report: ALK rearranged locally advanced lung adenocarcinoma showing inconsistent radiographic findings and pathological responses during neoadjuvant alectinib therapy
por: Cao, Peijun, et al.
Publicado: (2023)

Function-Wise Dual-Omics analysis for radiation pneumonitis prediction in lung cancer patients
por: Li, Bing, et al.
Publicado: (2022)

Clinical features and short-term outcomes of patients with COVID-19 due to different exposure history
por: Chen, Xianmeng, et al.
Publicado: (2020)

Indole-Based Small Molecules as Potential Therapeutic Agents for the Treatment of Fibrosis
por: Qin, Rui, et al.
Publicado: (2022)

Sequential treatment with alectinib in crizotinib-resistant non-small-cell lung cancer
por: Majumdar, Swaratika, et al.
Publicado: (2018)

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)
por: Watanabe, Satoshi, et al.
Publicado: (2022)

Chinese perspectives on clinical efficacy and safety of alectinib in patients with ALK-positive advanced non-small cell lung cancer
por: Yu, Hui, et al.
Publicado: (2019)

Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer
por: Kaznatcheev, Artem, et al.
Publicado: (2019)

Postoperative Long-Term Outcomes and Independent Risk Factors of Non-Small-Cell Lung Cancer Patients With Propofol versus Sevoflurane Anesthesia: A Retrospective Cohort Study
por: Gao, Zhenglian, et al.
Publicado: (2022)

Indole Alkaloids from Plants as Potential Leads for Antidepressant Drugs: A Mini Review
por: Hamid, Hazrulrizawati A., et al.
Publicado: (2017)

Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK‐rearranged non‐small cell lung cancer
por: Ando, Chihiro, et al.
Publicado: (2023)

Exposure–response analysis of alectinib in crizotinib-resistant ALK-positive non-small cell lung cancer
por: Morcos, Peter N., et al.
Publicado: (2018)

Anaplastic lymphoma kinase inhibition in metastatic non-small cell lung cancer: clinical impact of alectinib
por: Muller, Ittai B, et al.
Publicado: (2017)

Alectinib and Brigatinib: New Second-Generation ALK Inhibitors for the Treatment of Non–Small Cell Lung Cancer
por: Beardslee, Tyler, et al.
Publicado: (2018)

A Case of Advanced Non-Small-Cell Lung Cancer With Response to Alectinib and Favorable Quality of Life
por: Shrestha, Dhan B, et al.
Publicado: (2022)

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib
por: Sakamoto, Hiroaki, et al.
Publicado: (2021)

Alectinib-associated pneumoperitoneum in stage IV non-small cell lung cancer - A case report
por: Maina, Renee M., et al.
Publicado: (2022)

Bayesian analysis supports the role of alectinib and ensartinib for ALK‐positive non–small cell lung cancer
por: Rizzo, Alessandro
Publicado: (2023)

Radiation Recall Pneumonitis Anticipates Bilateral Immune-Induced Pneumonitis in Non-Small Cell Lung Cancer
por: Torresan, Sara, et al.
Publicado: (2023)

Regulation of the Ras-Related Signaling Pathway by Small Molecules Containing an Indole Core Scaffold: A Potential Antitumor Therapy
por: Chen, Fei-Yu, et al.
Publicado: (2020)

Case Report: Fatal Multiorgan Failure and Heterochronous Pneumonitis Following Pembrolizumab Treatment in a Patient With Large-Cell Neuroendocrine Carcinoma of Lung
por: Xie, Xiaohong, et al.
Publicado: (2021)

Alectinib for Miliary Lung Metastasis in ALK-Positive Lung Adenocarcinoma
por: Satoh, Hironori, et al.
Publicado: (2021)

miRNAs in anti-cancer drug resistance of non-small cell lung cancer: Recent advances and future potential
por: Yan, Hang, et al.
Publicado: (2022)

Alectinib-Induced Erythema Multiforme and Successful Rechallenge with Alectinib in a Patient with Anaplastic Lymphoma Kinase-Rearranged Lung Cancer
por: Kimura, Tatsuo, et al.
Publicado: (2016)

Successful treatment with crizotinib after alectinib-induced interstitial lung disease
por: Zhu, Ning, et al.
Publicado: (2021)

Long Non-Coding RNA in Drug Resistance of Non-Small Cell Lung Cancer: A Mini Review
por: Sun, Ruizheng, et al.
Publicado: (2019)

The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis
por: Ma, Ke, et al.
Publicado: (2018)

Comparison of Clinical Efficacy of Alectinib Versus Crizotinib in ALK-Positive Non-Small Cell Lung Cancer: A Meta-Analysis
por: Tang, Hao, et al.
Publicado: (2021)

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients
por: Wang, Cong, et al.
Publicado: (2018)

New Insights Into Gut-Bacteria-Derived Indole and Its Derivatives in Intestinal and Liver Diseases
por: Li, Xiaojing, et al.
Publicado: (2021)

ALK Rearrangement in Small-Cell Lung Cancer and Durable Response to Alectinib: A Case Report
por: Sun, Ning, et al.
Publicado: (2021)

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
por: Koizumi, Tomonobu, et al.
Publicado: (2016)

Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
por: Shaw, Alice T., et al.
Publicado: (2015)

Successful Treatment with Alectinib for Choroidal Metastasis in Anaplastic Lymphoma Kinase Rearranged Non-small Cell Lung Cancer
por: Funazo, Tomoko, et al.
Publicado: (2017)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

Letter: Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small-Cell Lung Cancer in China
por: Mu, Lifeng, et al.
Publicado: (2020)

Partial treatment response to alectinib in metastatic non-small cell lung cancer with KIDINS220-ALK fusion
por: Lei, Yanna, et al.
Publicado: (2023)

Application and Prospect of CRISPR/Cas9 Technology in Reversing Drug Resistance of Non-Small Cell Lung Cancer
por: Huang, Lu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_55k2q2fiq49bn6bvcjb4bdb50s